Edesa Biotech Free Cash Flow (FCF) History (EDSA)
Edesa Biotech reported −$6.6M in free cash flow for fiscal 2023, an increase of $5.6M from the previous fiscal year.
View full Edesa Biotech company overviewEdesa Biotech free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2023 | 2023-09-30 | −$6.6M | $5.6M | — | — |
| 2022 | 2022-09-30 | −$12.3M | $1.4M | — | — |
| 2021 | 2021-09-30 | −$13.7M | −$8.7M | — | — |
| 2020 | 2020-09-30 | −$5.0M | $7,119 | — | −1518.00% |
| 2018 | 2018-09-30 | −$5.0M | $4,067 | — | — |
| 2017 | 2017-09-30 | −$5.0M | −$94,482 | — | −10004.76% |
| 2016 | 2016-09-30 | −$4.9M | −$220,916 | — | −385.94% |
| 2015 | 2015-09-30 | −$4.7M | −$141,212 | — | −617.77% |
| 2014 | 2014-08-31 | −$4.5M | −$1.7M | — | −1221.55% |
| 2013 | 2013-08-31 | −$2.8M | $1.2M | — | −514.30% |
| 2012 | 2012-08-31 | −$4.0M | — | — | −1407.48% |
Edesa Biotech quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2023 | 2023-09-30 | −$1.5M | $4.2M | — | — |
| Q3 2023 | 2023-06-30 | −$1.8M | $1.2M | — | — |
| Q2 2023 | 2023-03-31 | −$1.6M | −$1.2M | — | — |
| Q1 2023 | 2022-12-31 | −$1.8M | $1.4M | — | — |
| Q4 2022 | 2022-09-30 | −$5.6M | −$5.3M | — | — |
| Q3 2022 | 2022-06-30 | −$3.0M | $94,881 | — | — |
| Q2 2022 | 2022-03-31 | −$417,853 | $6.8M | — | — |
| Q1 2022 | 2021-12-31 | −$3.2M | −$199,090 | — | — |
| Q4 2021 | 2021-09-30 | −$356,785 | $1.3M | — | — |
| Q3 2021 | 2021-06-30 | −$3.1M | −$1.8M | — | — |
| Q2 2021 | 2021-03-31 | −$7.2M | −$6.0M | — | — |
| Q1 2021 | 2020-12-31 | −$3.0M | −$2.2M | — | — |
| Q4 2020 | 2020-09-30 | −$1.7M | −$1.3M | — | −335393.60% |
| Q3 2020 | 2020-06-30 | −$1.4M | −$965,232 | — | −1230.39% |
| Q2 2020 | 2020-03-31 | −$1.2M | $388,257 | — | −1059.82% |
| Q1 2020 | 2019-12-31 | −$789,712 | $389,518 | — | −732.57% |
| Q2 2019 | 2019-03-31 | −$403,044 | $816,439 | — | — |
| Q1 2019 | 2018-12-31 | −$388,012 | $626,814 | — | — |
| Q2 2018 | 2018-03-31 | −$1.6M | −$240,914 | — | −2434.79% |
| Q1 2018 | 2017-12-31 | −$1.2M | $270,228 | — | −5755.99% |
| Q4 2017 | 2017-09-30 | −$1.2M | $79,597 | — | — |
| Q3 2017 | 2017-06-30 | −$1.0M | $83,226 | — | — |
| Q2 2017 | 2017-03-31 | −$1.3M | −$157,411 | — | −2092.41% |
| Q1 2017 | 2016-12-31 | −$1.4M | −$99,894 | — | −1021.78% |
| Q4 2016 | 2016-09-30 | −$1.3M | −$312,386 | — | −470.51% |
| Q3 2016 | 2016-06-30 | −$1.1M | −$36,914 | — | −606.35% |
| Q2 2016 | 2016-03-31 | −$1.2M | $153,555 | — | −355.83% |
| Q1 2016 | 2015-12-31 | −$1.3M | −$25,171 | — | −276.46% |
| Q4 2015 | 2015-09-30 | −$986,694 | −$379,627 | — | −491.74% |
| Q3 2015 | 2015-06-30 | −$1.1M | $66,724 | — | −672.68% |
| Q2 2015 | 2015-03-31 | −$1.3M | $200,067 | — | −700.73% |
| Q1 2015 | 2014-12-31 | −$1.3M | −$28,376 | — | −622.77% |
| Q4 2014 | 2014-08-31 | −$607,067 | — | — | −480.28% |
| Q3 2014 | 2014-06-30 | −$1.1M | — | — | −1554.86% |
| Q2 2014 | 2014-03-31 | −$1.5M | — | — | −1324.48% |
| Q1 2014 | 2013-12-31 | −$1.3M | — | — | −2203.17% |
Edesa Biotech free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$5.0M to −$6.6M, a net decrease of $1.6M. Edesa Biotech's latest reported quarter, Q4 2023, generated −$1.5M in free cash flow, an increase of $4.2M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Edesa Biotech filings at SEC.gov ↗